Visiongain has launched a new pharma report Antibiotics Market Report: By Class (Beta Lactam & Beta Lactamase, Quinolones, Macrolides, Others), by Drug Origin (Natural, Synthetic, Semi Synthetic), by Spectrum of Activity (Broad Spectrum, Narrow Spectrum), by Route of Administration (Oral, Intravenous, Others) and by Region.

Global Antibiotics Market is anticipated to grow on account of growing infectious diseases and health crisis. The global antibiotics market is anticipated to grow at a lucrative CAGR of 4.2% and anticipated to reach USD 71.64 Billion by 2029.

Antibiotics are strong drugs that combat certain infections and, when used correctly, can save life. They either prevent reproducing or destroying bacteria. The immune system can typically destroy them before bacteria can multiply and trigger symptoms. WBCs attack damaging bacteria, and the immune system can generally deal with and combat the infection even if symptoms do happen. However, sometimes the number of harmful bacteria is excessive, and they cannot be battled by the immune system. In this situation, antibiotics are helpful.

Some medical experts worry about overuse of antibiotics by individuals. They also think that this excessive use contributes to the increasing amount of bacterial diseases that become resistant to antibacterial drugs. Outpatient antibiotic overuse is a issue, according to the Centers for Disease Control (CDC). In some areas, such as the Southeast, antibiotic use seems to be greater. The use of carbapenems, a large class of last-line antibiotics, increased substantially between 2007 and 2010.

Rising infectious diseases along with an imbalance in antibiotic demand is the primary factor driving this market growth. Increasing attempts to develop sophisticated products by significant businesses will also promote market growth.

Collaborative development strategic plans for splitting costs are now frequently being introduced by market participants. This, in turn, is anticipated to result in more molecules developing. In addition, public-private partnerships will further promote the generation of fresh pipeline products where fund and innovative R&D methods are advanced by government bodies to antibiotics producers. For example, a five-year contract with AstraZeneca was signed by the Department of Health and Human Services in September 2015, where the former supplied USD 220 million for the exploration of two molecules, namely Aztreonam and Avibactam.

North America holds a significant market globally owing to increased adoption of antibiotics and growing healthcare expenditure across United States which holds maximum share in North America. On the other hand, Asia Pacific holds majority of market share and will continue to dominate in the future due to presence of large population and usage of generic medicines, coupled with funding for research institutes from the government.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.

The comprehensive market report features companies such as Abbott Laboratories, Eli Lilly, GlaxoSmithKline Plc, Johnson & Johnson, Bayer HealthCare Pharmaceuticals LLC, Bristol-Myers Squibb Co., Merck & Company, Inc., Pfizer, Inc., Roche Holding AG among other prominent players.

Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.